Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0356620150300040620
Journal of Korean Society of Endocrinology
2015 Volume.30 No. 4 p.620 ~ p.625
Refractory Graves¡¯ Disease Successfully Cured by Adjunctive Cholestyramine and Subsequent Total Thyroidectomy
:Yang Yeo-Ree
:Hwang Sea-Won/:Kim Min-Ji/:Lim Ye-Jee/:Kim Min-Hee/:Lee So-Hee/:Lim Dong-Jun/:Kang Moo-Il/:Cha Bong-Yun
Abstract
The three major forms of treatment for Graves thyrotoxicosis are antithyroid drugs, radioactive iodine therapy and thyroidectomy. Surgery is the definitive treatment for Graves thyrotoxicosis that is generally recommended when other treatments have failed or are contraindicated. Generally, thyrotoxic patients should be euthyroid before surgery to minimize potential complications which usually requires preoperative management with thionamides or inorganic iodine. But several cases of refractory Graves¡¯ disease have shown resistance to conventional treatment. Here we report a 40-year-old female patient with Graves¡¯ disease who complained of thyrotoxic symptoms for 7 months. Her thyroid function test and thyroid autoantibody profiles were consistent with Graves¡¯ disease. One kind of thionamides and ¥â-blocker were started to control her disease. However, she was resistant to nearly all conventional medical therapies, including ¥â-blockers, inorganic iodine, and two thionamides. She experienced hepatotoxicity from the thionamides. What was worse is her past history of serious allergic reaction to corticosteroids, which are often used to help control symptoms. A 2-week regimen of high-dose cholestyramine improved her uncontrolled thyrotoxicosis and subsequent thyroidectomy was successfully performed. In conclusion, cholestyramine could be administered as an effective and safe adjunctive agent for preoperative preparation in patients with severe hyperthyroid Graves¡¯s disease that is resistant to conventional therapies.
KEYWORD
Graves disease, Drug resistance, Cholestyramine resin
FullTexts / Linksout information
 
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø